Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Ali Hakan Kaya, Emre Tekgündüz, Kadir Ilkkiliç, Mehmet Sinan Dal, Alparslan Merdin, Abdullah Karakus, Sibel Kabukcu Hacioglu, Filiz Bekdemir, Merih Kızıl Çakar, Mehmet Hilmi Dogu, Mehmet Orhan Ayyildiz, Serdal Korkmaz & Fevzi Altuntaş. (2018) Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy. Journal of Chemotherapy 30:1, pages 44-48.
Read now
Read now
Christan M. Thomas, Cindy Ippoliti, Gail J. Roboz, Eric Feldman, Dimitrios Savva, Sara James & Koen van Besien. (2017) Clofarabine as a bridge to hematopoietic stem cell transplant. Leukemia & Lymphoma 58:1, pages 230-232.
Read now
Read now
Claudia Loeffler, Markus Kapp, Goetz-Ulrich Grigoleit, Stephan Mielke, Jürgen Loeffler, Peter U. Heuschmann, Uwe Malzahn, Elke Hupp, Hermann Einsele & Gernot Stuhler. (2015) Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. Leukemia & Lymphoma 56:12, pages 3365-3369.
Read now
Read now
Imit Kaur, Jonathan E Constance, Ken M Kosak, Michael G Spigarelli & Catherine MT Sherwin. (2015) An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 53-65.
Read now
Read now
Jeffrey Bryan, Hagop Kantarjian, Hillary Prescott & Elias Jabbour. (2014)
Clofarabine in the treatment of myelodysplastic syndromes. Expert Opinion on Investigational Drugs 23:2, pages 255-263.
Read now
Read now
Deepa Sampath & Guillermo Garcia-Manero. (2012) Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leukemia & Lymphoma 53:6, pages 1013-1014.
Read now
Read now
David Claxton, Harry P. Erba, Stefan Faderl, Martha Arellano, Roger M. Lyons, Tibor Kovacsovics, Janice Gabrilove, Dirk Huebner, Pritesh J. Gandhi & Hagop Kantarjian. (2012) Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leukemia & Lymphoma 53:3, pages 435-440.
Read now
Read now
Tadeusz Robak. (2011) New nucleoside analogs for patients with hematological malignancies. Expert Opinion on Investigational Drugs 20:3, pages 343-359.
Read now
Read now
A Pession, R Masetti, K Kleinschmidt & A Martoni. (2010) Use of clofarabine for acute childhood leukemia. Biologics: Targets and Therapy 4, pages 111-118.
Read now
Read now
Keeran Sampat, Hagop Kantarjian & Gautam Borthakur. (2009) Clofarabine: emerging role in leukemias. Expert Opinion on Investigational Drugs 18:10, pages 1559-1564.
Read now
Read now
Melissa L Larson & Parameswaran Venugopal. (2009) Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opinion on Pharmacotherapy 10:8, pages 1353-1357.
Read now
Read now
Articles from other publishers (50)
Qi-Ying Liao, Chao Ma, Yu-Chao Wang, Shao-Qian Yang, Jiang-Shan Ma & Zhi-Tao He. (2023) Enantioselective and stereodivergent hydromonofluoroalkylation of conjugated and remote dienes. Chinese Chemical Letters 34:12, pages 108371.
Crossref
Crossref
Dan-Xia Ying, Peng-Cheng Zhao, Wen Zhang & Guo-Wu Rao. (2023) Research Progress in Competitive Purine Antagonists. Current Medicinal Chemistry 30:34, pages 3880-3904.
Crossref
Crossref
Stefano D'Errico, Andrea Patrizia Falanga, Francesca Greco, Gennaro Piccialli, Giorgia Oliviero & Nicola Borbone. (2023) State of art in the chemistry of nucleoside-based Pt(II) complexes. Bioorganic Chemistry 131, pages 106325.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
7
159
.
Syed Saqib Ali, Ruchika Raj, Tejinder Kaur, Brenna Weadick, Debasis Nayak, Minnsung No, Jane Protos, Hannah Odom, Kajal Desai, Avinash K. Persaud, Joanne Wang & Rajgopal Govindarajan. (2022) Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective. Cancers 14:13, pages 3113.
Crossref
Crossref
Sarah E. Huff, Jordan M. Winter & Chris G. Dealwis. (2022) Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules 12:6, pages 815.
Crossref
Crossref
Meiqi Lu, Liangxiang Xiao, Bo Xu & Qing Gao. (2022) Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic Methods. The Tohoku Journal of Experimental Medicine 258:2, pages 79-90.
Crossref
Crossref
A.G. Nerkar, G.S. Chakraborthy & R. D. Ukirde. (2021) Anti-cancer agents from natural sources: A review. Current Trends in Pharmacy and Pharmaceutical Chemistry 3:4, pages 38-46.
Crossref
Crossref
Hiroshi Yamada, Satoshi Taniguchi, Masayuki Shimojima, Long Tan, Miyuki Kimura, Yoshitomo Morinaga, Takasuke Fukuhara, Yoshiharu Matsuura, Takashi Komeno, Yousuke Furuta, Masayuki Saijo & Hideki Tani. (2021) M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening. Viruses 13:6, pages 1061.
Crossref
Crossref
Harinder Gill, Rita Yim, Herbert H. Pang, Paul Lee, Thomas S. Y. Chan, Yu‐Yan Hwang, Garret M. K. Leung, Ho‐Wan Ip, Rock Y. Y. Leung, Sze‐Fai Yip, Bonnie Kho, Harold K. K. Lee, Vivien Mak, Chi‐Chung Chan, June S. M. Lau, Chi‐Kuen Lau, Shek‐Yin Lin, Raymond S. M. Wong, Wa Li, Edmond S. K. Ma, Jun Li, Gianni Panagiotou, Joycelyn P. Y. Sim, Albert K. W. Lie & Yok‐Lam Kwong. (2020) Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. Cancer Medicine 9:10, pages 3371-3382.
Crossref
Crossref
Jinhan Xie, Miriam Span, Erik van Maarseveen, Jurgen Langenhorst, Alan V. Boddy, Keith C.S. Sia, Rosemary Sutton, Nicola Venn, Arjen M. Punt, Vanessa Tyrrell, Michelle Haber, Toby Trahair, Loretta Lau, Glenn M. Marshall & Richard B. Lock. (2019) Optimization of a clofarabine‐based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer 67:4.
Crossref
Crossref
Elias Jabbour, Stefan Faderl, Koji Sasaki, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Keyur Patel, Joseph D. Khoury, Carlos Bueso‐Ramos, Zachary Bohannan, Farhad Ravandi, Gautam Borthakur, Srdan Verstovsek, Darla Miller, Rita Maduike, Chitra Hosing, Hagop M. Kantarjian & Guillermo Garcia‐Manero. (2016) Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123:4, pages 629-637.
Crossref
Crossref
Gheath Alatrash, Peter F. Thall, Benigno C. Valdez, Patricia S. Fox, Jing Ning, Haven R. Garber, Selma Janbey, Laura L. Worth, Uday Popat, Chitra Hosing, Amin M. Alousi, Partow Kebriaei, Elizabeth J. Shpall, Roy B. Jones, Marcos de Lima, Gabriela Rondon, Julianne Chen, Richard E. Champlin & Borje S. Andersson. (2016) Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation 22:10, pages 1792-1800.
Crossref
Crossref
Katsuyoshi Koh, Chitose Ogawa, Yasuhiro Okamoto, Kazuko Kudo, Jiro Inagaki, Tsuyoshi Morimoto, Hideya Mizukami, Evelyne Ecstein-Fraisse & Atsushi Kikuta. (2016) Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. International Journal of Hematology 104:2, pages 245-255.
Crossref
Crossref
A Lu, Y Fang, X Du, Y Li, Z Cai, K Yu, L Zhao, B Wang, J Wu, Y Cheng, Y Zuo, Y Jia, F Tan, L Ding, J Lu, L Zhang & X Huang. (2016) Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study. Blood Cancer Journal 6:2, pages e400-e400.
Crossref
Crossref
Venkatesh K. Rudrapatna, Kimberly Morley, Kenneth M. Boucher, Andrew S. Pierson, Christian T. Shull, James P. Kushner & Paul J. Shami. (2015) Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leukemia Research 39:8, pages 835-839.
Crossref
Crossref
E Sokolowski, C B Turina, K Kikuchi, D M Langenau & C Keller. (2013) Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene 33:15, pages 1877-1889.
Crossref
Crossref
Pawel Robak & Tadeusz Robak. (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treatment Reviews 39:8, pages 851-861.
Crossref
Crossref
Franco Locatelli, Francesca Moretta & Sergio Rutella. (2013) Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. Current Opinion in Oncology 25:6, pages 707-715.
Crossref
Crossref
Carlos E. Vigil, Wei Tan, George Deeb, Sheila N. Sait, Annemarie W. Block, Petr Starostik, Elizabeth A. Griffiths, James E. Thompson, Jessica D. Greene, Laurie A. Ford, Eunice S. Wang & Meir Wetzler. (2013) Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia Research 37:11, pages 1468-1471.
Crossref
Crossref
Aziz Nazha, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Sangbum Choi, Guillermo Garcia‐Manero, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, Jorge Cortes, Alessandra Ferrajoli, Steve Kornblau, Naval Daver, Naveen Pemmaraju, Michael Andreeff, Zeev Estrov, Min Du, Mark Brandt & Stefan Faderl. (2013) Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology 88:11, pages 961-966.
Crossref
Crossref
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour. (2013) Novel treatment options for acute myelocytic leukemia. Clinical Investigation 3:10, pages 979-990.
Crossref
Crossref
Stephen Tiley & David Claxton. (2012) Clofarabine in the treatment of acute myeloid leukemia in older adults. Therapeutic Advances in Hematology 4:1, pages 5-13.
Crossref
Crossref
Abeer Abd Elmoneim, Lia Gore, Rebecca M. Ricklis, Jessica Boklan, Todd Cooper, Aru Narendran, Katherine Rolla, Tammy Scott & Robert J. Arceci. (2012) Phase I dose‐escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatric Blood & Cancer 59:7, pages 1252-1258.
Crossref
Crossref
Chengzhi Xie, Holly Edwards, Salvatore B. LoGrasso, Steven A. Buck, Larry H. Matherly, Jeffrey W. Taub & Yubin Ge. (2012) Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood & Cancer 59:7, pages 1245-1251.
Crossref
Crossref
Pascale Trioche, Brigitte Nelken, Gérard Michel, Isabelle Pellier, Arnaud Petit, Yves Bertrand, Pierre Rohrlich, Claudine Schmitt, Nicolas Sirvent, Patrick Boutard, Geneviève Margueritte, Brigitte Pautard, Stéphane Ducassou, Dominique Plantaz, Alain Robert, Caroline Thomas, Kristell Desseaux, Sylvie Chevret & André Baruchel. (2012) French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Experimental Hematology & Oncology 1:1.
Crossref
Crossref
Franco Locatelli, Martin Schrappe, Maria Ester BernardoSergio Rutella. (2012) How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120:14, pages 2807-2816.
Crossref
Crossref
Stefan Faderl, Guillermo Garcia‐Manero, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Zeev Estrov, Varsha Gandhi, Anna L. Byrd, Monica Kwari, Jorge Cortes & Hagop M. Kantarjian. (2011) A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher‐risk myelodysplastic syndrome. Cancer 118:3, pages 722-728.
Crossref
Crossref
Sergio Amadori, Roberto Stasi, Alberto M. Martelli, Adriano Venditti, Giovanna Meloni, Fabrizio Pane, Giovanni Martinelli, Monia Lunghi, Livio Pagano, Daniela Cilloni, Elena Rossetti, Francesco Di Raimondo, Claudio Fozza, Luciana Annino, Francesca Chiarini, Francesca Ricci, Emanuele Ammatuna, Edoardo La Sala, Paola Fazi & Marco Vignetti. (2012) Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). British Journal of Haematology 156:2, pages 205-212.
Crossref
Crossref
Borje S. Andersson, Benigno C. Valdez, Marcos de Lima, Xuemei Wang, Peter F. Thall, Laura L. Worth, Uday Popat, Timothy Madden, Chitra Hosing, Amin Alousi, Gabriela Rondon, Partow Kebriaei, Elizabeth J. Shpall, Roy B. Jones & Richard E. Champlin. (2011) Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biology of Blood and Marrow Transplantation 17:6, pages 893-900.
Crossref
Crossref
Chadi Nabhan, Nancy Davis, Jacob D. Bitran, Angel Galvez, Walter Fried, Kathy Tolzien, Susan Foss, Wendy M. Dewey & Parameswaran Venugopal. (2010) Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients. Cancer 117:7, pages 1490-1497.
Crossref
Crossref
Shinjiro Nagai, Kazumasa Takenaka, Deepa Nachagari, Charles Rose, Kali Domoney, Daxi Sun, Alex Sparreboom & John D. Schuetz. (2011) Deoxycytidine Kinase Modulates the Impact of the ABC Transporter ABCG2 on Clofarabine Cytotoxicity. Cancer Research 71:5, pages 1781-1791.
Crossref
Crossref
Felicetto Ferrara. (2011) Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical Challenge. Clinical Lymphoma Myeloma and Leukemia 11:1, pages 10-16.
Crossref
Crossref
Benigno C. Valdez, Yang Li, David Murray, Richard E. Champlin & Borje S. Andersson. (2011) The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochemical Pharmacology 81:2, pages 222-232.
Crossref
Crossref
Paul S. Gaynon & Theresa M. Harned. 2011. New Agents for the Treatment of Acute Lymphoblastic Leukemia. New Agents for the Treatment of Acute Lymphoblastic Leukemia
311
327
.
Benigno C. Valdez & Borje S. Andersson. (2010) Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environmental and Molecular Mutagenesis 51:6, pages 659-668.
Crossref
Crossref
Stefan FaderlGuillermo Garcia-ManeroZeev EstrovFarhad RavandiGautam BorthakurJorge E. CortesSusan O'BrienVarsha GandhiWilliam PlunkettAnna ByrdMonica KwariHagop M. Kantarjian. (2010) Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. Journal of Clinical Oncology 28:16, pages 2755-2760.
Crossref
Crossref
Claire Seedhouse, Martin Grundy, Shili Shang, John Ronan, Heather Pimblett, Nigel Russell & Monica Pallis. (2009) Impaired S-Phase Arrest in Acute Myeloid Leukemia Cells with a FLT3 Internal Tandem Duplication Treated with Clofarabine. Clinical Cancer Research 15:23, pages 7291-7298.
Crossref
Crossref
B N Savani, S Mielke, N Reddy, S Goodman, M Jagasia & K Rezvani. (2009) Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplantation 44:12, pages 769-777.
Crossref
Crossref
Anna Zhenchuk, Koroush Lotfi, Gunnar Juliusson & Freidoun Albertioni. (2009) Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochemical Pharmacology 78:11, pages 1351-1359.
Crossref
Crossref
Franco Locatelli, Anna M. Testi, Maria Ester Bernardo, Carmelo Rizzari, Alice Bertaina, Pietro Merli, Andrea Pession, Eugenia Giraldi, Rosanna Parasole, Walter Barberi & Marco Zecca. (2009) Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. British Journal of Haematology 147:3, pages 371-378.
Crossref
Crossref
Hans-Jochem Kolb, Belinda Simoes & Christoph Schmid. (2009) Stem cell transplants for patients with relapsed/refractory leukaemia. Current Opinion in Hematology 16:6, pages 444-452.
Crossref
Crossref
David Schiff, Patrick Y. Wen & Martin J. van den Bent. (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nature Reviews Clinical Oncology 6:10, pages 596-603.
Crossref
Crossref
Eric Solary, Vincent Ribrag & Stéphane de Botton. 2009. ABC Transporters and Multidrug Resistance. ABC Transporters and Multidrug Resistance
315
347
.
Mats Ljungman. (2009) Targeting the DNA Damage Response in Cancer. Chemical Reviews 109:7, pages 2929-2950.
Crossref
Crossref
William B. Parker, Sue C. Shaddix, Karen S. Gilbert, Rodney V. Shepherd & William R. Waud. (2008) Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine. Cancer Chemotherapy and Pharmacology 64:2, pages 253-261.
Crossref
Crossref
Sandra Liekens, Annelies Bronckaers & Jan Balzarini. (2009) Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes. The Lancet Oncology 10:6, pages 628-635.
Crossref
Crossref
Felicetto Ferrara, Salvatore Palmieri, Mariangela Pedata, Assunta Viola, Tiziana Izzo, Clelia Criscuolo & Giuseppina Mele. (2009) Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematological Oncology 27:1, pages 40-45.
Crossref
Crossref
Pellegrino Musto & Felicetto Ferrara. (2008) Clofarabine. Cancer 113:8, pages 1995-1998.
Crossref
Crossref
Chad M. Craig & Gary J. Schiller. (2008) Acute myeloid leukemia in the elderly: Conventional and novel treatment approaches. Blood Reviews 22:4, pages 221-234.
Crossref
Crossref